Allovir Stock Performance
| ALVR Stock | USD 0.45 0.01 2.17% |
The firm shows a Beta (market volatility) of 1.93, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Allovir will likely underperform. At this point, Allovir has a negative expected return of -0.51%. Please make sure to confirm Allovir's standard deviation, potential upside, as well as the relationship between the Potential Upside and day median price , to decide if Allovir performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Allovir has generated negative risk-adjusted returns adding no value to investors with long positions. Even with weak performance in the last few months, the Stock's basic indicators remain relatively invariable which may send shares a bit higher in January 2025. The latest agitation may also be a sign of long-running up-swing for the enterprise retail investors. ...more
1 | Disposition of 301 shares by Brett Hagen of Allovir at 0.8148 subject to Rule 16b-3 | 10/03/2024 |
2 | Allovir executive sells shares to cover tax withholding obligations | 10/04/2024 |
3 | Disposition of 635 shares by Miller Edward of Allovir at 0.779 subject to Rule 16b-3 | 10/21/2024 |
4 | Disposition of 766 shares by Miller Edward of Allovir at 0.7678 subject to Rule 16b-3 | 10/22/2024 |
5 | Allovirs general counsel Edward Miller sells 1,082 in stock | 10/23/2024 |
6 | AlloVir Will Have To Spend Its Cash Wisely | 10/29/2024 |
7 | Disposition of 5136 shares by Sinha Vikas of Allovir at 0.8649 subject to Rule 16b-3 | 11/05/2024 |
8 | Disposition of 2272 shares by Miller Edward of Allovir at 0.8649 subject to Rule 16b-3 | 11/06/2024 |
9 | AlloVir and Kalaris Therapeutics Announce Agreement for Transformational Merger to Create Company Focused on Diseases of the Retina | 11/08/2024 |
10 | Disposition of 8706 shares by Brainard Diana of Allovir at 0.5485 subject to Rule 16b-3 | 11/19/2024 |
11 | SHAREHOLDER INVESTIGATION Halper Sadeh LLC Investigates ALVR, STAF, AE on Behalf of Shareholders | 12/04/2024 |
12 | Disposition of 57549 shares by Miller Edward of Allovir subject to Rule 16b-3 | 12/11/2024 |
13 | Allovir stock touches 52-week low at 0.47 amid market challenges - Investing.com | 12/12/2024 |
| Begin Period Cash Flow | 106.9 M |
Allovir |
Allovir Relative Risk vs. Return Landscape
If you would invest 76.00 in Allovir on September 16, 2024 and sell it today you would lose (31.00) from holding Allovir or give up 40.79% of portfolio value over 90 days. Allovir is currently does not generate positive expected returns and assumes 7.136% risk (volatility on return distribution) over the 90 days horizon. In different words, 63% of stocks are less volatile than Allovir, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Allovir Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Allovir's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Allovir, and traders can use it to determine the average amount a Allovir's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0714
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | ALVR |
Estimated Market Risk
| 7.14 actual daily | 63 63% of assets are less volatile |
Expected Return
| -0.51 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.07 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Allovir is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Allovir by adding Allovir to a well-diversified portfolio.
Allovir Fundamentals Growth
Allovir Stock prices reflect investors' perceptions of the future prospects and financial health of Allovir, and Allovir fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Allovir Stock performance.
| Return On Equity | -0.8 | ||||
| Return On Asset | -0.37 | ||||
| Current Valuation | (69.85 M) | ||||
| Shares Outstanding | 115.36 M | ||||
| Price To Book | 0.43 X | ||||
| Gross Profit | 165 K | ||||
| EBITDA | (190.15 M) | ||||
| Net Income | (190.42 M) | ||||
| Cash And Equivalents | 172.67 M | ||||
| Cash Per Share | 1.91 X | ||||
| Total Debt | 27.43 M | ||||
| Debt To Equity | 0.14 % | ||||
| Current Ratio | 8.18 X | ||||
| Book Value Per Share | 1.05 X | ||||
| Cash Flow From Operations | (124.45 M) | ||||
| Earnings Per Share | (0.90) X | ||||
| Market Capitalization | 85.25 M | ||||
| Total Asset | 190.8 M | ||||
| Retained Earnings | (656.19 M) | ||||
| Working Capital | 159.27 M | ||||
| Current Asset | 61.62 M | ||||
| Current Liabilities | 53.23 M | ||||
About Allovir Performance
Assessing Allovir's fundamental ratios provides investors with valuable insights into Allovir's financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Allovir is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | (25.69) | (26.98) | |
| Return On Tangible Assets | (1.00) | (0.95) | |
| Return On Capital Employed | (1.12) | (1.17) | |
| Return On Assets | (1.00) | (0.95) | |
| Return On Equity | (1.31) | (1.24) |
Things to note about Allovir performance evaluation
Checking the ongoing alerts about Allovir for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Allovir help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Allovir generated a negative expected return over the last 90 days | |
| Allovir has high historical volatility and very poor performance | |
| Allovir has some characteristics of a very speculative penny stock | |
| Allovir has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (190.42 M) with profit before overhead, payroll, taxes, and interest of 165 K. | |
| Allovir currently holds about 172.67 M in cash with (124.45 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.91, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Allovir has a poor financial position based on the latest SEC disclosures | |
| Roughly 49.0% of the company shares are held by company insiders | |
| Latest headline from news.google.com: Allovir stock touches 52-week low at 0.47 amid market challenges - Investing.com |
- Analyzing Allovir's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Allovir's stock is overvalued or undervalued compared to its peers.
- Examining Allovir's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Allovir's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Allovir's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Allovir's stock. These opinions can provide insight into Allovir's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Allovir Stock Analysis
When running Allovir's price analysis, check to measure Allovir's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Allovir is operating at the current time. Most of Allovir's value examination focuses on studying past and present price action to predict the probability of Allovir's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Allovir's price. Additionally, you may evaluate how the addition of Allovir to your portfolios can decrease your overall portfolio volatility.